Get the Stockscreener App
0.682
2.10%
0.012
Ovid Therapeutics Inc stock is traded at $0.682, with a volume of 103.24K.
It is up +2.10% in the last 24 hours and down -16.64% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$0.67
Open:
$0.6682
24h Volume:
103.24K
Relative Volume:
0.29
Market Cap:
$49.04M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.9093
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+3.51%
1M Performance:
-16.64%
6M Performance:
-23.62%
1Y Performance:
-82.32%
1-Day Range:
$0.6682
$0.70
1-Week Range:
$0.65
$0.7186
52-Week Range:
$0.65
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.6841 | 49.04M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.75 | 120.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.71 | 77.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.77 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 35.23B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
116.30 | 28.29B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Dup15q Syndrome Drugs Market Size Report 2032 | Ovid - openPR
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat
Oppenheimer raises Ovid stock rating, sets $4 price target - MSN
Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN
Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN
Ovid therapeutics president and COO acquires $4,971 in stock - MSN
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance
Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Barclays PLC Acquires 63,702 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Insider Activity Raises Eyebrows! Key Moves at Ovid Therapeutics! - Jomfruland.net
Ovid Therapeutics Insider Ups Holding During Year - Yahoo Finance
Short Interest in Ovid Therapeutics Inc. (NASDAQ:OVID) Decreases By 27.0% - MarketBeat
Jane Street Group LLC Has $45,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - Defense World
Ovid’s Gameplan: Flicking The Master Switch In Neurology - News & Insights
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Geode Capital Management LLC Acquires 14,816 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Acquired by Barclays PLC - Defense World
Fragile X Syndrome Market Expected to rise, 2034 | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia - Barchart
Ovid Therapeutics Inc (NASDAQ: OVID) Drops -2.44 Percent In Recent Trading, What Questions Do You Have? - Stocks Register
Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest - MarketBeat
Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935 - Reuters
Fmr LLC Acquires 47,723 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - MarketBeat
Verition Fund Management LLC Makes New Investment in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
3 US Penny Stocks With Market Caps Over $20M - Simply Wall St
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors - citybiz
HC Wainwright Has Bullish Estimate for OVID FY2024 Earnings - MarketBeat
HC Wainwright Has Strong Forecast for OVID FY2024 Earnings - Defense World
KCC2 activation nears inflection point - BioCentury
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Ovid Therapeutics to Present Multiple Posters Supporting - GlobeNewswire
Ovid Therapeutics Unveils Breakthrough Epilepsy Treatment Data at Major Conference | OVID Stock News - StockTitan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Analysts - MarketBeat
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEVIN JEREMY M | CEO |
Mar 18 '24 |
Buy |
2.76 |
18,248 |
50,364 |
3,616,715 |
0.50%
1.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):